MEI Pharma, Inc. (NASDAQ:MEIP)
CAPS Rating:
A development stage company, engaged in the clinical development of the anti-cancer drug phenoxodiol.
Thousands of investors, millions in profit
A development stage company, engaged in the clinical development of the anti-cancer drug phenoxodiol.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Seeking Alpha puff pieces notwithstanding, the long term prospects for Marshall Edwards remain dim. The company continues to putter with the dregs of the plant flavonoid oncology pipeline inherited from Daddy Novogen, another dead stock walking. The million or two that the company can raise from dilutive financings every quarter aren't likely to be sufficient to complete any phase II trials. Keep in mind this is a 12M cap stock, and in the wacky world of nano-cap anything can happen in the short term.